|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000133422 |
Summary for MORC2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000133422 | Gene symbol | MORC2 |
| Gene name | MORC family CW-type zinc finger 2 | |
| HGNC | 23573 | |
| Entrez ID | 22880 | |
| Gene type | protein_coding | |
| Synonyms | MORC2|ZCW3|KIAA0852|AC004542.C22.1 | |
| UniProtAcc | Q9Y6X9 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for MORC2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MORC2 | 2.67e+03 | 1.09e+00 | 2.19e-01 | 4.99e+00 | 5.96e-07 | 4.49e-06 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MORC2 | 1.72e+03 | 1.05e+00 | 1.62e-01 | 6.46e+00 | 1.05e-10 | 2.86e-09 | READ |
Top |
Sex-biased somatic mutation for MORC2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for MORC2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg08087379 | chr22:30968288 | CGI:chr22:30968578-30969589 | UTR,promoter,exon,gene body | 7.63e-01 | 9.06e-01 | -2.69e+00 | 7.20e-03 | 1.01e-02 | -1.43e-01 |
| LUAD | cg12449837 | chr22:30968370 | CGI:chr22:30968578-30969589 | promoter | 6.67e-01 | 8.01e-01 | -2.65e+00 | 7.94e-03 | 1.10e-02 | -1.34e-01 |
| THCA | cg12449837 | chr22:30968370 | CGI:chr22:30968578-30969589 | promoter | 6.66e-01 | 5.58e-01 | 2.38e+00 | 1.73e-02 | 2.44e-02 | 1.08e-01 |
| BLCA | cg17098449 | chr22:30968363 | CGI:chr22:30968578-30969589 | promoter | 8.57e-01 | 9.61e-01 | -2.54e+00 | 1.10e-02 | 1.52e-02 | -1.04e-01 |
| ESCA | cg08087379 | chr22:30968288 | CGI:chr22:30968578-30969589 | UTR,promoter,exon,gene body | 7.44e-01 | 8.78e-01 | -2.14e+00 | 3.20e-02 | 4.44e-02 | -1.34e-01 |
| ESCA | cg12449837 | chr22:30968370 | CGI:chr22:30968578-30969589 | promoter | 6.31e-01 | 8.23e-01 | -2.18e+00 | 2.90e-02 | 4.34e-02 | -1.92e-01 |
| CHOL | cg04270033 | chr22:30968318 | CGI:chr22:30968578-30969589 | promoter | 6.21e-01 | 8.84e-01 | -2.21e+00 | 2.70e-02 | 3.50e-02 | -2.63e-01 |
| CHOL | cg17098449 | chr22:30968363 | CGI:chr22:30968578-30969589 | promoter | 6.72e-01 | 9.45e-01 | -2.58e+00 | 9.87e-03 | 2.15e-02 | -2.73e-01 |
| CHOL | cg12449837 | chr22:30968370 | CGI:chr22:30968578-30969589 | promoter | 4.72e-01 | 7.24e-01 | -2.43e+00 | 1.50e-02 | 2.65e-02 | -2.52e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg05373339 | chr22:30968316 | CGI:chr22:30968578-30969589 | promoter | 6.58e-01 | 5.00e-01 | 2.71e+00 | 6.78e-03 | 1.33e-02 | 1.58e-01 |
| KIRC | cg12449837 | chr22:30968370 | CGI:chr22:30968578-30969589 | promoter | 7.28e-01 | 5.72e-01 | 2.27e+00 | 2.34e-02 | 3.00e-02 | 1.55e-01 |
| COAD | cg12449837 | chr22:30968370 | CGI:chr22:30968578-30969589 | promoter | 8.25e-01 | 9.32e-01 | -2.74e+00 | 6.11e-03 | 1.10e-02 | -1.08e-01 |
| LIHC | cg17098449 | chr22:30968363 | CGI:chr22:30968578-30969589 | promoter | 8.48e-01 | 9.58e-01 | -2.96e+00 | 3.07e-03 | 5.45e-03 | -1.10e-01 |
| KIRP | cg12449837 | chr22:30968370 | CGI:chr22:30968578-30969589 | promoter | 7.72e-01 | 6.26e-01 | 2.80e+00 | 5.08e-03 | 1.08e-02 | 1.46e-01 |
Top |
Exon skipping events with PSI in TCGA for MORC2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for MORC2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for MORC2 |
| TFs related to MORC2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| MORC2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for MORC2 |
| RBPs related to ES in MORC2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | BRUNOL6 | exon_skip_368696 | 8.42e+00 | 1.54e-02 | 8.96e+00 | 9.80e-01 | Female-biased |
| MESO | BRUNOL6 | exon_skip_368696 | 8.39e+00 | 3.81e-03 | 8.83e+00 | 9.91e-01 | Female-biased |
| KICH | BRUNOL6 | exon_skip_368696 | 8.83e+00 | 9.91e-01 | 8.43e+00 | 4.14e-03 | Male-biased |
| MORC2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs1004890 | chr22:37696885:G:A | - | 0.165719255898181 | 0.0470633729218664 | GBM | Female-baised eQTL |
| rs62236743 | chr22:37700046:T:C | - | 0.165719255898181 | 0.0470633729218664 | GBM | Female-baised eQTL |
| rs13056151 | chr22:23309131:G:A | - | 0.125620742235879 | 0.0394147850833403 | LGG | Female-baised eQTL |
| rs144310924 | chr22:33130957:C:T | - | 0.07527744939318 | 0.00411827605706067 | LUAD | Female-baised eQTL |
| rs2413052 | chr22:31387795:T:C | - | -0.0494031242032844 | 0.00720383489839883 | LUAD | Female-baised eQTL |
| rs5753723 | chr22:31606308:T:C | - | 0.0481322937822541 | 0.00924872239705308 | LUAD | Female-baised eQTL |
| rs12053772 | chr22:33829177:T:C | - | 0.0694498019235909 | 0.0124302906440807 | LUAD | Female-baised eQTL |
| rs1968023 | chr22:31546784:G:A | - | -0.0400898825695338 | 0.042006908136146 | LUAD | Female-baised eQTL |
| rs4616575 | chr22:29010088:T:G | - | -0.036395725743276 | 0.0452168935799663 | LUAD | Female-baised eQTL |
| rs137619 | chr22:39310355:A:C | - | -0.0337555232385702 | 0.046041749573724 | LUAD | Female-baised eQTL |
| rs9613768 | chr22:29006844:G:T | - | -0.0389014826782841 | 0.0462762688697471 | LUAD | Female-baised eQTL |
| rs4594553 | chr22:29010067:T:C | - | -0.0359229959455983 | 0.0472322648481513 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs5754158 | chr22:32580365:G:A | - | 0.08073087266013 | 0.013353687704731 | LIHC | Male-baised eQTL |
| rs9608666 | chr22:28120044:T:C | - | 0.105305383235275 | 0.0120128507690041 | BLCA | Male-baised eQTL |
| rs146311092 | chr22:28133794:G:A | - | 0.104552577083006 | 0.0132090207479676 | BLCA | Male-baised eQTL |
| rs9613560 | chr22:28008179:T:C | - | 0.104481282548605 | 0.0133198721097828 | BLCA | Male-baised eQTL |
| rs76804938 | chr22:28500152:T:C | - | 0.101213988214244 | 0.0170844919417812 | BLCA | Male-baised eQTL |
| rs9613558 | chr22:27982700:C:G | - | 0.102517645783327 | 0.0194022059736665 | BLCA | Male-baised eQTL |
| rs12484825 | chr22:28290034:T:A | - | 0.0979913136206365 | 0.0254583965236704 | BLCA | Male-baised eQTL |
| rs5755767 | chr22:35584013:A:G | - | 0.051407657085814 | 0.029141831349618 | BLCA | Male-baised eQTL |
| rs17409164 | chr22:28238683:A:G | - | 0.0976886891881823 | 0.0291601323592406 | BLCA | Male-baised eQTL |
| rs9613589 | chr22:28299519:A:G | - | 0.0949512795712082 | 0.0297587696878446 | BLCA | Male-baised eQTL |
| rs192780973 | chr22:28334262:T:G | - | 0.094911692503485 | 0.0299758447593101 | BLCA | Male-baised eQTL |
| rs9613593 | chr22:28335589:T:G | - | 0.094911692503485 | 0.0299758447593101 | BLCA | Male-baised eQTL |
| rs17480516 | chr22:27892544:G:A | - | 0.0916728438540917 | 0.036894379877761 | BLCA | Male-baised eQTL |
| rs9608690 | chr22:28525359:G:A | - | 0.0931217404107473 | 0.0398754510450305 | BLCA | Male-baised eQTL |
| rs5755766 | chr22:35582779:G:A | - | 0.0512892896148403 | 0.0437587281667443 | BLCA | Male-baised eQTL |
| rs738398 | chr22:28251435:A:G | - | 0.0911272154772313 | 0.0492725290391601 | BLCA | Male-baised eQTL |
| rs2413429 | chr22:36893827:A:G | - | -0.0686748337676013 | 0.00288743381233146 | COAD | Male-baised eQTL |
| rs5756389 | chr22:36894505:A:T | - | -0.0686010482546009 | 0.00462767465152676 | COAD | Male-baised eQTL |
| rs735561 | chr22:36900957:G:A | - | -0.0687383515874245 | 0.00469139825628796 | COAD | Male-baised eQTL |
| rs4821557 | chr22:36903457:A:G | - | -0.0681885793609039 | 0.00529790125117277 | COAD | Male-baised eQTL |
| rs6004688 | chr22:25508779:C:T | - | 0.0723755626167157 | 0.00854769305793645 | COAD | Male-baised eQTL |
| rs58327654 | chr22:33330020:C:A | - | 0.142583426628985 | 0.0201572994898996 | COAD | Male-baised eQTL |
| rs9610606 | chr22:36919625:G:A | - | -0.0582908212143186 | 0.0256410453591177 | COAD | Male-baised eQTL |
| rs7287536 | chr22:35119272:G:A | - | -0.0902865742775332 | 0.0270550738905657 | COAD | Male-baised eQTL |
| rs5756407 | chr22:36920217:T:C | - | -0.0577684040462466 | 0.0280750002740106 | COAD | Male-baised eQTL |
| rs2899251 | chr22:35530420:C:G | - | -0.0772617791886355 | 0.0297765010639982 | COAD | Male-baised eQTL |
| rs11705504 | chr22:36921451:G:A | - | -0.0570506380925592 | 0.0326489223701146 | COAD | Male-baised eQTL |
| rs134710 | chr22:26108036:A:G | - | 0.0832042302548508 | 0.0331980107296836 | COAD | Male-baised eQTL |
| rs4821411 | chr22:35529949:G:A | - | -0.0778025612845026 | 0.0353133736439188 | COAD | Male-baised eQTL |
| rs5760389 | chr22:24388083:A:T | - | 0.116778874811535 | 0.0408296854652348 | COAD | Male-baised eQTL |
| rs4645084 | chr22:37412082:G:C | - | 0.0730766599795835 | 0.046789292333381 | COAD | Male-baised eQTL |
| rs132743 | chr22:36208428:C:G | - | -0.102881115267908 | 0.0475391187697786 | COAD | Male-baised eQTL |
| rs132744 | chr22:36208559:T:C | - | -0.102881115267908 | 0.0475391187697786 | COAD | Male-baised eQTL |
| rs5755586 | chr22:35121961:A:G | - | -0.0828925218982198 | 0.0485352931048276 | COAD | Male-baised eQTL |
| rs5754090 | chr22:32449416:A:G | - | 0.0629434007961608 | 0.0493552458766109 | COAD | Male-baised eQTL |
| rs1964803 | chr22:25515806:A:G | - | 0.0681969922704161 | 0.0496808831756412 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000133422 |
| CpG Site: cg08087379 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.386242461783073 | |
| Female Effect: - | |
 | Gene ID: ENSG00000133422 |
| CpG Site: cg04270033 | |
| Position to Gene: promoter | |
| Male Effect: -0.386242461783073 | |
| Female Effect: - | |
 | Gene ID: ENSG00000133422 |
| CpG Site: cg12449837 | |
| Position to Gene: promoter | |
| Male Effect: -0.195308399749716 | |
| Female Effect: - | |
 | Gene ID: ENSG00000133422 |
| CpG Site: cg04270033 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.386553015026817 | |
 | Gene ID: ENSG00000133422 |
| CpG Site: cg08087379 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: - | |
| Female Effect: -0.232615665839929 | |
 | Gene ID: ENSG00000133422 |
| CpG Site: cg17098449 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.371057963200161 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg08087379 | chr22:30968288 | gene,exon,promoter,UTR | -0.386242461783073 | 1.73799465044731e-11 | -0.4962794528574205 | 6.784195409492843e-14 | KIRP |
| cg04270033 | chr22:30968318 | promoter | -0.386242461783073 | 1.73799465044731e-11 | -0.4962794528574205 | 6.784195409492843e-14 | KIRP |
| cg12449837 | chr22:30968370 | promoter | -0.195308399749716 | 2.11553032677062e-05 | -0.3573215202158833 | 1.9165985841326653e-07 | KIRP |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg04270033 | chr22:30968318 | promoter | -0.386553015026817 | 2.83582933049077e-10 | -0.44100868664564136 | 1.638984185387524e-13 | LUAD |
| cg08087379 | chr22:30968288 | gene,exon,promoter,UTR | -0.232615665839929 | 5.10976819907545e-07 | -0.374779055167197 | 7.385720262261975e-10 | LUAD |
| cg17098449 | chr22:30968363 | promoter | -0.371057963200161 | 5.98636598714901e-05 | -0.31170309039855815 | 8.806608879771691e-07 | LGG |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of MORC2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000133422 | MORC2 | C0007959 | Charcot-Marie-Tooth Disease | 1 | CTD_human |
| ENSG00000133422 | MORC2 | C0205713 | Roussy-Levy Syndrome (disorder) | 1 | CTD_human |
| ENSG00000133422 | MORC2 | C0270911 | Charcot-Marie-Tooth Disease, Type Ia (disorder) | 1 | CTD_human |
| ENSG00000133422 | MORC2 | C0270912 | Charcot-Marie-Tooth Disease, Type Ib | 1 | CTD_human |
| ENSG00000133422 | MORC2 | C0270914 | Hereditary Motor and Sensory-Neuropathy Type II | 1 | CTD_human |
| ENSG00000133422 | MORC2 | C0751036 | Hereditary Motor and Sensory Neuropathy Type I | 1 | CTD_human |
| ENSG00000133422 | MORC2 | C4225243 | CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Z | 1 | CTD_human |
